In addition, HMA treatment can significantly improve the expression of several immune checkpoint molecules on MDS cells such as PD-L1, Tim-3 and CD47, providing a theoretical basis for the mechanism of HMA resistance and the combination therapy with immune checkpoint molecular inhibitors (61). Here, HAVCR2 is linked to myelodysplastic syndrome.